BBOT
BridgeBio Oncology Therapeutics, Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$713.09M
P/E Ratio
—
EPS
$-4.30
Beta
0.51
52W High
$14.87
52W Low
$8.51
50-Day MA
$10.30
200-Day MA
$11.05
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About BridgeBio Oncology Therapeutics, Inc.
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of small molecule inhibitor for cancer patients. The company is headquartered in South San Francisco, California.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-145.54M |
| Operating Margin | 0.00% |
| Return on Equity | -48.20% |
| Return on Assets | -29.70% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $5.14 |
| Price-to-Book | 1.74 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $80.03M |
| Float | $31.16M |
| % Insiders | 27.23% |
| % Institutions | 70.14% |
Analyst Ratings
Consensus ($25.38 target)
3
Strong Buy6
BuyData last updated: 4/7/2026